Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1980 3
1981 1
1984 3
1986 3
1987 2
1988 1
1989 3
1991 1
1992 6
1993 1
1994 1
1995 7
1996 2
1997 6
1998 5
1999 5
2000 3
2001 6
2002 4
2003 5
2004 2
2005 5
2006 8
2007 6
2008 10
2009 7
2010 9
2011 5
2012 15
2013 12
2014 13
2015 8
2016 7
2017 9
2018 14
2019 19
2020 11
2021 15
2022 9
2023 15
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

236 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Hong RL, González Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D; KEYNOTE-048 Investigators. Burtness B, et al. Lancet. 2019 Nov 23;394(10212):1915-1928. doi: 10.1016/S0140-6736(19)32591-7. Epub 2019 Nov 1. Lancet. 2019. PMID: 31679945 Clinical Trial.
Investigators, participants, and representatives of the sponsor were masked to the PD-L1 combined positive score (CPS) results; PD-L1 positivity was not required for study entry. ...Adverse events led to death in 25 (8%) participants in the pembrolizumab alone group, 32 (1 …
Investigators, participants, and representatives of the sponsor were masked to the PD-L1 combined positive score (CPS) results; PD-L1 …
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.
Kojima T, Shah MA, Muro K, Francois E, Adenis A, Hsu CH, Doi T, Moriwaki T, Kim SB, Lee SH, Bennouna J, Kato K, Shen L, Enzinger P, Qin SK, Ferreira P, Chen J, Girotto G, de la Fouchardiere C, Senellart H, Al-Rajabi R, Lordick F, Wang R, Suryawanshi S, Bhagia P, Kang SP, Metges JP; KEYNOTE-181 Investigators. Kojima T, et al. J Clin Oncol. 2020 Dec 10;38(35):4138-4148. doi: 10.1200/JCO.20.01888. Epub 2020 Oct 7. J Clin Oncol. 2020. PMID: 33026938 Clinical Trial.
PATIENTS AND METHODS: In this open-label, phase III study, we randomly assigned (1:1) 628 patients with advanced/metastatic squamous cell carcinoma or adenocarcinoma of the esophagus, that progressed after one prior therapy, to pembrolizumab 200 mg eve …
PATIENTS AND METHODS: In this open-label, phase III study, we randomly assigned (1:1) 628 patients with advanced/metastatic squamo …
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, Le QT, Lee NY, Leidner R, Lewis RL, Licitra L, Mehanna H, Mell LK, Raben A, Sikora AG, Uppaluri R, Whitworth F, Zandberg DP, Ferris RL. Cohen EEW, et al. J Immunother Cancer. 2019 Jul 15;7(1):184. doi: 10.1186/s40425-019-0662-5. J Immunother Cancer. 2019. PMID: 31307547 Free PMC article. Clinical Trial.
Improvement in outcomes are needed for patients with recurrent and or metastatic squamous cell carcinoma of the head and neck (HNSCC). In 2016, the US Food and Drug Administration (FDA) granted the first immunotherapeutic approvals - the anti-PD-1 immu …
Improvement in outcomes are needed for patients with recurrent and or metastatic squamous cell carcinoma of the …
Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651.
Haddad RI, Harrington K, Tahara M, Ferris RL, Gillison M, Fayette J, Daste A, Koralewski P, Zurawski B, Taberna M, Saba NF, Mak M, Kawecki A, Girotto G, Alvarez Avitia MA, Even C, Toledo JGR, Guminski A, Müller-Richter U, Kiyota N, Roberts M, Khan TA, Miller-Moslin K, Wei L, Argiris A. Haddad RI, et al. J Clin Oncol. 2023 Apr 20;41(12):2166-2180. doi: 10.1200/JCO.22.00332. Epub 2022 Dec 6. J Clin Oncol. 2023. PMID: 36473143 Free PMC article. Clinical Trial.
PURPOSE: CheckMate 651 (ClinicalTrials.gov identifier: NCT02741570) evaluated first-line nivolumab plus ipilimumab versus EXTREME (cetuximab plus cisplatin/carboplatin plus fluorouracil six cycles, then cetuximab maintenance) in recurrent/metastatic squamous cell …
PURPOSE: CheckMate 651 (ClinicalTrials.gov identifier: NCT02741570) evaluated first-line nivolumab plus ipilimumab versus EXTREME (cetuximab …
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Docampo LCI, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison ML. Ferris RL, et al. Oral Oncol. 2018 Jun;81:45-51. doi: 10.1016/j.oraloncology.2018.04.008. Epub 2018 Apr 17. Oral Oncol. 2018. PMID: 29884413 Free PMC article. Clinical Trial.
Estimated OS rates at 18, 24, and 30 months with nivolumab were consistent irrespective of PD-L1 expression (<1%/1%). In the nivolumab arm, there were no observed differences in baseline characteristics or safety profile between long-term survivors and the overall popul …
Estimated OS rates at 18, 24, and 30 months with nivolumab were consistent irrespective of PD-L1 expression (<1%/1%). In the nivolumab ar …
Effects of Pembrolizumab in Recurrent/Metastatic Squamous Cell Head and Neck Carcinoma: A Multicenter Retrospective Study.
Okada T, Fushimi C, Matsuki T, Tokashiki K, Takahashi H, Okamoto I, Sato H, Kondo T, Hanyu K, Kishida T, Ito T, Yamashita G, Masubuchi T, Tada Y, Miura K, Omura GO, Yamashita T, Oridate N, Tsukahara K. Okada T, et al. Anticancer Res. 2023 Jun;43(6):2717-2724. doi: 10.21873/anticanres.16438. Anticancer Res. 2023. PMID: 37247908
BACKGROUND/AIM: Pembrolizumab exhibits anticancer efficacy in platinum-sensitive or platinum-unfit patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). ...CONCLUSION: The real-world therapeutic effect of pembroli …
BACKGROUND/AIM: Pembrolizumab exhibits anticancer efficacy in platinum-sensitive or platinum-unfit patients with recurrent/metastatic …
Systemic treatment of metastatic squamous cell carcinoma of the head and neck: proposal for management changes.
Peyrade F, Borel C, Daste A, Even C, Saada-Bouzid E, Guigay J. Peyrade F, et al. Curr Opin Oncol. 2021 May 1;33(3):160-167. doi: 10.1097/CCO.0000000000000738. Curr Opin Oncol. 2021. PMID: 33782359 Review.
Twelve French medical oncologist involved in the management of R/M SCCHNC for more than 10 years examined the literature and proposed a simple and practical management based on five criteria: age, delay from last platinum injection, combined positive score expression level …
Twelve French medical oncologist involved in the management of R/M SCCHNC for more than 10 years examined the literature and proposed a simp …
Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck.
Saada-Bouzid E, Peyrade F, Guigay J. Saada-Bouzid E, et al. Curr Opin Oncol. 2019 May;31(3):146-151. doi: 10.1097/CCO.0000000000000522. Curr Opin Oncol. 2019. PMID: 30893146 Review.
PURPOSE OF REVIEW: Checkpoint inhibitors (CPI) are revolutionizing the treatment of advanced cancers including recurrent and or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN). ...In the KEYNOTE-048 trial, the pembrolizumab was also …
PURPOSE OF REVIEW: Checkpoint inhibitors (CPI) are revolutionizing the treatment of advanced cancers including recurrent and or metastati …
Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
Łasińska I, Kolenda T, Teresiak A, Lamperska KM, Galus Ł, Mackiewicz J. Łasińska I, et al. Anticancer Agents Med Chem. 2019;19(3):290-303. doi: 10.2174/1871520618666180910092356. Anticancer Agents Med Chem. 2019. PMID: 30198439 Review.
Even in the cases of primary radical treatment (surgical, concomitant chemoradiotherapy or radiotherapy alone), subsequent local recurrence or distant metastases are often observed. In patients with recurrent disease who are unable to receive radical treatment, the results …
Even in the cases of primary radical treatment (surgical, concomitant chemoradiotherapy or radiotherapy alone), subsequent local recurrence …
Cetuximab in the treatment of squamous cell carcinoma of the head and neck.
Specenier P, Vermorken JB. Specenier P, et al. Expert Rev Anticancer Ther. 2011 Apr;11(4):511-24. doi: 10.1586/era.11.20. Expert Rev Anticancer Ther. 2011. PMID: 21504318 Review.
In the EXTREME trial, the addition of cetuximab to platinum/5-fluorouracil as first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck not only led to significant improvements in survival, response rate and disease cont …
In the EXTREME trial, the addition of cetuximab to platinum/5-fluorouracil as first-line treatment of recurrent/metastatic squamou …
236 results